Difference between revisions of "Team:SDU-Denmark/Tour10"

 
(33 intermediate revisions by 6 users not shown)
Line 1: Line 1:
 
{{:Team:SDU-Denmark/core/header| }}
 
{{:Team:SDU-Denmark/core/header| }}
 
<html>
 
<html>
<div>
+
 
<p> <i> "Change is the law of life and  those who look only to the past or present are certain to miss the future." - <b>John F. Kennedy</b></i> </p>  
+
<p> <i> "Change is the law of life and  those who look only to the past or present are certain to miss the future." - <b>John F. Kennedy</b></i> </p>  
 
<h1 align="center"> Project description </h1>  
 
<h1 align="center"> Project description </h1>  
<p>
 
  
  
<span class="intro">Monoclonal antibodies (mAbs) are extensively used</span> in scientific and fundamental medical research. They are used to purify, detect and tag proteins, in diagnostics and treatments of diseases, just to mention some of the many purposes of mAbs. As schematized underneath, the production as it is, can be interpreted as consuming on multiple levels. We thought it was time for a skeptical approach, which is what our project is all about.
+
<div class="thumb tright">
   
+
<div class="thumbinner" style="width:155px;heigth:245px;">
</p>
+
<a class="popupImg alignRight" style="width:150px" target="_blank" href="https://static.igem.org/mediawiki/2015/6/6a/SDU2015_Babymice.png" title="Baby mice who will be brought up as laboratory animals and used for antibody production. The aim of this project is to find an alternative to the use of animals in the antibody production.">
<p>  
+
   <img src="https://static.igem.org/mediawiki/2015/6/6a/SDU2015_Babymice.png" style="width:150px"/>   
<a class="popupImg alignRight" style="width:250px" target="_blank" href="https://static.igem.org/mediawiki/2015/6/6a/SDU2015_Babymice.png" title="Baby mice who will be brought up as laboratory animals and used for antibody production.">
+
   <img src="https://static.igem.org/mediawiki/2015/6/6a/SDU2015_Babymice.png" style="width:250px"/>   
+
 
</a>
 
</a>
<span class="intro">The nowadays production methods of mAbs</span> are not only time-consuming and costly but are at the expense of animal lives. Antibodies have many applications in research, diagnostics, and show great promise in treatment of cancer. But the advancement is held back due to the expensive and tiresome production. Therefore we propose an alternative to antibodies; peptide aptamers – produced in Escherichia coli (E. coli). The variable loop of the peptide aptamer is generated through a random nucleotide library and held together by an enzymatic inactive version of human Thioredoxin (hTrx) as a scaffold protein. We are using the bacterial two-hybrid system to screen for functioning peptide aptamers that are able to bind our chosen target proteins (‘antigens’). In this model bacteria expressing a functioning peptide aptamer will express Red Fluorescent Protein (RFP), which enables us to isolate them. To challenge the antibody tradition, we are also proposing a production model.  
+
<div class="thumbcaption">Figure 1: Photo of baby mice taken at the animal facilities at Odense University Hospital (OUH). </div>
 +
</div>
 +
</div>
 +
 
 +
<div class="thumb tright">
 +
<div class="thumbinner" style="width:155px;heigth:245px;">
 +
<a class="popupImg alignRight" style="width:150px" target="_blank" href="https://static.igem.org/mediawiki/2015/3/38/SDU2015_Gallery_WorkingintheLaboratort.png" title="Team members working in the laboratory. Finding a solution for the alternative to traditional antibody production.">
 +
  <img src="https://static.igem.org/mediawiki/2015/3/38/SDU2015_Gallery_WorkingintheLaboratort.png" style="width:150px"/> 
 +
</a>
 +
<div class="thumbcaption">Figure 2: Members of the team discussing something in the laboratory. </div>
 +
</div>
 +
</div>
 +
 
 +
<p>
 +
<span class="intro">Monoclonal antibodies (mAbs) are extensively used in scientific and fundamental medical research</span>.    
  
 +
The nowadays production methods of mAbs are not only time-consuming and costly but also at the expense of animal lives. Antibodies have many applications in research, diagnostics and show great promise in treatment of cancer. But the advancement is held back due to the expensive and time consuming production. Therefore we propose an alternative to antibodies; peptide aptamers – produced in <i>Escherichia coli</i> (<i>E. coli</i>). The variable loop of the peptide aptamer is generated through a random nucleotide library and held together by an optimized, enzymatic inactive version of human Thioredoxin (hTrx) used as a scaffold protein. We are using the bacterial two-hybrid system to generate and, at the same time, screen for peptide aptamers with desired properties. Additionally we are proposing a production model. 
 
</p>
 
</p>
 +
 +
 +
  
 
<p>
 
<p>
<a class="popupImg alignLeft" style="width:250px" target="_blank" href="https://static.igem.org/mediawiki/2015/3/38/SDU2015_Gallery_WorkingintheLaboratort.png" title="Some of our team members working in the laboratory.">
+
<span class="intro">Our team consists</span> of nine students from five different educations; philosophy, chemical engineering, biochemistry and molecular biology, biomedicine and medicine. During the last 6 months we have laughed, cried, built friendships and overcome a lot of struggles together. In the end of the day it has been a whole lot of fun! To guide and help us through the journey, we have had our four supervisors. Go to the next page <a href="https://2015.igem.org/Team:SDU-Denmark/Tour11">the team</a> and dig deeper into the members of the SDU Denmark 2015 iGEM team.  
  <img src="https://static.igem.org/mediawiki/2015/3/38/SDU2015_Gallery_WorkingintheLaboratort.png" style="width:250px"/> 
+
</a>
+
<span class="intro">Our team consists</span> of nine students from five different educations; philosophy, chemical engineering, biochemistry and molecular biology, biomedicine and medicine. During this last 6 months we have laughed, cried, built friendships and overcome a lot of struggles together. In the end of the day it has just been a whole lot of fun! To guide and help us through the journey we have had our four supervisors.  
+
  
 
<br>
 
<br>
 
<br>
 
<br>
<br>
+
<br><br><br>
<br>
+
<br><br><br>
<br>
+
 
+
 
</p>
 
</p>
  
</div>
+
 
 
</html>
 
</html>
  
 
{{:Team:SDU-Denmark/core/footer}}
 
{{:Team:SDU-Denmark/core/footer}}

Latest revision as of 03:28, 19 September 2015

"Change is the law of life and those who look only to the past or present are certain to miss the future." - John F. Kennedy

Project description

Figure 1: Photo of baby mice taken at the animal facilities at Odense University Hospital (OUH).
Figure 2: Members of the team discussing something in the laboratory.

Monoclonal antibodies (mAbs) are extensively used in scientific and fundamental medical research. The nowadays production methods of mAbs are not only time-consuming and costly but also at the expense of animal lives. Antibodies have many applications in research, diagnostics and show great promise in treatment of cancer. But the advancement is held back due to the expensive and time consuming production. Therefore we propose an alternative to antibodies; peptide aptamers – produced in Escherichia coli (E. coli). The variable loop of the peptide aptamer is generated through a random nucleotide library and held together by an optimized, enzymatic inactive version of human Thioredoxin (hTrx) used as a scaffold protein. We are using the bacterial two-hybrid system to generate and, at the same time, screen for peptide aptamers with desired properties. Additionally we are proposing a production model.

Our team consists of nine students from five different educations; philosophy, chemical engineering, biochemistry and molecular biology, biomedicine and medicine. During the last 6 months we have laughed, cried, built friendships and overcome a lot of struggles together. In the end of the day it has been a whole lot of fun! To guide and help us through the journey, we have had our four supervisors. Go to the next page the team and dig deeper into the members of the SDU Denmark 2015 iGEM team.